

Curriculum Vitae

Personal information

First name(s) / Surname(s) PALLESCHI MICHELA
Address(es) Via Cerenzia, 35 00178 Roma, Italia
Telephone(s) +39 347 488 6271
Mail michela.palleschi@irst.emr.it

C.F.: PLLMHL85R67H501D

Desired employment / Occupational field MEDICAL ONCOLOGY

Work experience Fellowship in Translational Genomics and Targeted Therapeutics in Solid Tumors Lab - IDIBAPS
Department of Medical Oncology - Breast Cancer Unit - Hospital Clínic de Barcelona 11 April- 10 May 2023

Dates (from – to) June 2018 -present
Occupation or position held Medical Oncologist Doctor

Name and address of employer Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I.R.C.C.S.
Via Piero Maroncelli, 40 47014 Meldola (FC)

Dates (from – to) August 2016 to June 2018

Oncology Division A. National Cancer Institute Regina Elena, Elio Chianesi 53 Street, 00144 Rome-

I.R.C.C.S.

Supervisione delle attività di dottorato del candidato Filippo Merloni, PhD al programma di dottorato in oncologia, ematologia e patologia. Alma Mater Studiorum, Università di Bologna – Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale – DIMES.

Periodo 01/10/2025 – In corso

Datore di lavoro Struttura Complessa di Oncologia Medica a Direzione Universitaria (UNIBO) Breast & GYN Unit, per conto di Alma Mater Studiorum, Università di Bologna.

Lezioni di oncologia medica agli studenti laureandi e specializzandi

Occupazione Nominato cultore della materia

Attività principali e responsabilità: Lezioni relative al Corso di Laurea CdL Medicina e Chirurgia – Alma Mater Studiorum,

Università di Bologna sede di Forlì a.a. 2025-2026 e 2026-2027. Lezioni agli specializzandi in Oncologia Medica, Cure Palliative e Ginecologia per i relativi corsi di specializzazione medica c/o Alma Mater di Bologna.

Occupation or position held	PhD Student																			
Name and address of employer	Alma Mater Studiorum, Bologna																			
Type of business or sector	November 2020-November 2023																			
Title of qualification awarded	PhD, Excellent, 18th March 2024																			
Principal subjects/occupational skills covered	Title of the final thesis: Exploring the role of rare germline variants in non-coding regions of cancer predisposition genes in triple-negative breast cancer patients																			
Occupation or position held	MEDICAL ONCOLOGIST ON CONTRACT																			
Name and address of employer																				
Type of business or sector	June 2011- June 2016																			
Title of qualification awarded	SPECIALIZATION IN MEDICAL ONCOLOGY, 70/70 cum Laude																			
Principal subjects/occupational skills covered	Title of the final thesis: "Genomic and Transcriptomic Characterization of resected squamous-cell lung cancer: Research of molecular alterations as a possible target of therapy "																			
Name and type of organisation providing education and training	University of Rome "Sapienza"																			
Dates (from-to)	July 29th 2010																			
Title of qualification awarded	Medical doctor degree 110/110 cum laude																			
Principal subjects/occupational skills covered	Title of the final thesis: "Fulvestrant in postmenopausal patients with advanced breast cancer: A real life single centre experience "																			
Name and type of organisation providing education and training	University of Rome "Sapienza"																			
Mother Tongue	ITALIAN																			
Other language(s)																				
Self-assessment European level (*)	<table border="1"> <thead> <tr> <th colspan="2">Understanding</th> <th colspan="2">Speaking</th> <th>Writing</th> </tr> <tr> <th>Listening</th> <th>Reading</th> <th>Spoken interaction</th> <th>Spoken production</th> <th></th> </tr> </thead> <tbody> <tr> <td>Good</td> <td>Good</td> <td>Good</td> <td>Good</td> <td>Good</td> </tr> </tbody> </table>					Understanding		Speaking		Writing	Listening	Reading	Spoken interaction	Spoken production		Good	Good	Good	Good	Good
Understanding		Speaking		Writing																
Listening	Reading	Spoken interaction	Spoken production																	
Good	Good	Good	Good	Good																
ENGLISH	(*) <u>Common European Framework of Reference for Languages</u>																			
Social skills and competences	Excellent interpersonal skills with colleagues and patients, improved with clinical practice																			

Organisational skills and competences

Excellent ability to organize teamwork

Computer skills and competences

Excellent ability to use the personal computer. Good knowledge of Microsoft Office and excellent knowledge of Internet Explorer and Mozilla Firefox.

Driving licence

DRIVING LICENSE B

Annexes

Reviewer activity

Publications

Meetings

Since 2010 I have attended in a several clinical studies in GCP as a Sub Investigator and Principal Investigator, Phase I-II-III trials.

REVIEWER ACTIVITY:

Frontiers in Oncology

PUBBLICATION:

Cortesi E, **Palleschi M**, Magri V, Naso G. The promise of liquid biopsy in cancer: a clinical perspective. *Chin J Cancer Res.* 2015;27(5):488–490. doi:10.3978/j.issn.1000-9604.2015.10.01J *Cell Physiol.* 2016 Nov 11. doi: 10.1002/jcp.25685.

Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, **Palleschi M**, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. *J Cell Physiol.* 2017;232(6):1571–1578. doi:10.1002/jcp.25685

Rocca A, Melegari E, **Palleschi M**. Precision medicine: PI3K targeting in advanced breast cancer. *Breast Cancer Res Treat.* 2019;178(2):479. doi:10.1007/s10549-019-05409-3

Palleschi M, Maltoni R, Sarti S, Melegari E, Bravaccini S, Rocca A. Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? [published online ahead of print, 2019 Oct 14]. *Breast J.* 2019;10.1111/tbj.13662. doi:10.1111/tbj.13662

Rocca A, Melegari E, **Palleschi M**. Ribociclib and Endocrine Therapy in Breast Cancer. *N Engl J Med.* 2019;381(16):1592. doi:10.1056/NEJMc1911188

Maltoni R, **Palleschi M**, Altini M, et al. Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? [published online ahead of print, 2020 Mar 19]. Clin Breast Cancer. 2020;S1526-8209(20)30026-4. doi:10.1016/j.clbc.2020.01.010

Palleschi M, Maltoni R, Barzotti E, et al. Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. World J Clin Cases. 2020;8(3):517–521. doi:10.12998/wjcc.v8.i3.517

Sara Bravaccini, Sara Ravaoli, Maria Tumedei, Andrea Rocca, **Michela Palleschi**, Maurizio Puccetti, Paola Parrella, Mattia Altini, and Roberta Maltoni Atezolizumab plus nab-paclitaxel in PD-L1 positive TNBC - Letter" Clinical Cancer Research [IN PRESS]

Maltoni R 1*, **Palleschi M***, Gallerani G Bravaccini S Cecconetto L , Melegari E, Altini M. Rocca A Impressive longterm response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: a case report" Medicine

Roberta Maltoni 1**, **Michela Palleschi**, ** Sara Ravaoli 1,* , Maria Maddalena Tumedei 1 , Andrea Rocca 1 , Elisabetta Melegari 1 , Mattia Altini 1 , Maurizio Puccetti 2 , Silvia Manunta 1 , Sara Bravaccini Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cance Cell Transplantation

Ravaoli S, Limarzi F, Tumedei MM, **Palleschi M**, Maltoni R, Bravaccini S. Are we ready to use TMB in breast cancer clinical practice? Cancer Immunol Immunother. 2020 Oct;69(10):1943-1945. doi: 10.1007/s00262-020-02682-w. Epub 2020 Jul 28. PMID: 32725361.

Palleschi M, Maltoni R, Ravaoli S, Vagheggini A, Mannozi F, Fanini F, Pirini F, Tumedei MM, Barzotti E, Cecconetto L, Sarti S, Manunta S, Possanzini P, Fedeli A, Curcio A, Altini M, De Giorgi U, Rocca A, Bravaccini S. Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience. Diagnostics (Basel). 2020 Aug 8;10(8):573. doi: 10.3390/diagnostics10080573. PMID: 32784518; PMCID: PMC7460222.

Maltoni R, **Palleschi M**, Ravaoli S, Tumedei MM, Altini M, Bravaccini S. Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold. Diagn Pathol. 2020 Sep 11;15(1):109. doi: 10.1186/s13000-020-01024-9. PMID: 32917222; PMCID: PMC7488398.

Palleschi M, Scarpi E, Casadei C. Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? Breast Cancer Res Treat. 2020 Sep 14. doi: 10.1007/s10549-020-05923-9. Epub ahead of print. PMID: 32929569.

Palleschi M, Iaia M.L., Casadei C Germline BRCA-mutated metastatic breast cancer with positive hormone receptor. Breast Cancer Res Treat.

Brighi N, Conteduca V, Lolli C, Gurioli G, Schepisi G, **Palleschi M**, Mariotti M, Casadei C, De Giorgi U. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Crit Rev Oncol Hematol. 2021 Jan;157:103199. doi: 10.1016/j.critrevonc.2020.103199. Epub 2020 Dec 13.

Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, **Palleschi M**, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). Clin Cancer Res. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482.

Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoidi M, Pedani F, Magri V, **Palleschi M**, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F; AINO (Associazione Italiana Neuro-Oncologia). Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncol. 2021 Sep;17(26):3445-3456. doi: 10.2217/fon-2021-0300. Epub 2021 May 28. PMID: 34044585.

Rossi T, **Palleschi M**, Angeli D, Tebaldi M, Martinelli G, Vannini I, Puccetti M, Limarzi F, Maltoni R, Gallerani G, Fabbri F. Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. Front Med (Lausanne). 2021 Jun 24;8:689895. doi: 10.3389/fmed.2021.689895. PMID: 34249978; PMCID: PMC8264184.

Palleschi M, Tedaldi G, Sirico M, Virga A, Ulivi P, De Giorgi U. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. Int J Mol Sci. 2021 Jul 23;22(15):7884. doi: 10.3390/ijms22157884. PMID: 34360649; PMCID: PMC8346118.

Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, Lorusso V, Cannita K, Arpino G, Stani S, **Palleschi M**, Rossello R, Sarobba G, Fabbri A, Giampaglia M, Pellegrini P, Adamo V, Morelli F, Barberi V, Ferretti G, Catania G, Pisegna S, Cognetti F, Giannarelli D. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice? Oncology. 2021 Dec 7. doi: 10.1159/000521252. Epub ahead of print. PMID: 34875670.

Palleschi M, Prochowski Iamurri A, Scarpi E, Mariotti M, Maltoni R, Mannozi F, Barone D, Paganelli G, Casi M, Giampalma E, De Giorgi U, Rocca A. Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab. Sci Rep. 2022 Mar 1;12(1):3385. doi: 10.1038/s41598-022-07143-1. PMID: 35233007; PMCID: PMC8888586.

Vannini I, Urbini M, Melloni M, Rossi T, Gallerani G, **Palleschi M**, Azzali I, Puccetti M, Martinelli G, Fabbri F. Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. Front Med (Lausanne). 2022 Mar 9;9:827206. doi: 10.3389/fmed.2022.827206. PMID: 35355608; PMCID: PMC8959346.

Gianni C, **Palleschi M**, Schepisi G, Casadei C, Bleve S, Merloni F, Sirico M, Sarti S, Cecconetto L, Di Menna G, Schettini F, De Giorgi U. Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment. Front Oncol. 2022

Aug 8;12:882896. doi: 10.3389/fonc.2022.882896. PMID: 36003772; PMCID: PMC9393759.

Rossi T, Angeli D, Tebaldi M, Fici P, Rossi E, Rocca A, **Palleschi M**, Maltoni R, Martinelli G, Fabbri F, Gallerani G. Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis. *Cancers (Basel)*. 2022 Aug 14;14(16):3925. doi: 10.3390/cancers14163925. PMID: 36010918; PMCID: PMC9405921.

Del Re M, Crucitta S, Omarini C, Bargagna I, Mongillo M, **Palleschi M**, Stucci S, Meattini I, D'Onofrio R, Lorenzini G, Biondani P, De Giorgi U, Porta C, Livi L, Natalizio S, Fontana A, Giontella E, Angelini L, Fogli S, Danesi R. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. *Breast*. 2022 Dec;66:157-161. doi: 10.1016/j.breast.2022.10.005. Epub 2022 Oct 15. PMID: 36283134; PMCID: PMC9593796.

Gianni C, **Palleschi M**, Merloni F, Di Menna G, Sirico M, Sarti S, Virga A, Ulivi P, Cecconetto L, Mariotti M, De Giorgi U. Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. *Int J Mol Sci*. 2022 Nov 17;23(22):14197. doi: 10.3390/ijms232214197. PMID: 36430675; PMCID: PMC9695769.

Sirico M, Virga A, Conte B, Urbini M, Ulivi P, Gianni C, Merloni F, **Palleschi M**, Gasperoni M, Curcio A, Saha D, Buono G, Muñoz M, De Giorgi U, Schettini F. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives. *Crit Rev Oncol Hematol*. 2023 Jan;181:103900. doi: 10.1016/j.critrevonc.2022.103900. Epub 2022 Dec 21. PMID: 36565894.

Gianni C, **Palleschi M**, Merloni F, Bleve S, Casadei C, Sirico M, Di Menna G, Sarti S, Cecconetto L, Mariotti M, De Giorgi U. Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. *Cancers (Basel)*. 2022 Dec 23;15(1):96. doi: 10.3390/cancers15010096. PMID: 36612091; PMCID: PMC9817806.

Merloni F, **Palleschi M**, Gianni C, Casadei C, Curcio A, Romeo A, Rocchi M, Cima S, Sirico M, Sarti S, Cecconetto L, Mariotti M, Di Menna G, De Giorgi U. Locoregional treatment of *de novo* stage IV breast cancer in the era of modern oncology. *Front Oncol*. 2023 Jan 30;13:1083297. doi: 10.3389/fonc.2023.1083297. PMID: 36793604; PMCID: PMC9923000.

Schepisi G, Gianni C, **Palleschi M**, Bleve S, Casadei C, Lolli C, Ridolfi L, Martinelli G, De Giorgi U. The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. *Cancers (Basel)*. 2023 Mar 4;15(5):1597. doi: 10.3390/cancers15051597. PMID: 36900394; PMCID: PMC10000829.

Merloni F, **Palleschi M**, Casadei C, Romeo A, Curcio A, Casadei R, Stella F, Ercolani G, Gianni C, Sirico M, Cima S, Sarti S, Cecconetto L, Di Menna G, De Giorgi U. Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure. *Ther Adv Med Oncol*. 2023 Mar 18;15:17588359231161412. doi: 10.1177/17588359231161412. PMID: 36950272; PMCID: PMC10026139.

Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, **Palleschi M**, Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG). Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. *JAMA Oncol.* 2023 Sep 1;9(9):1267-1272. doi: 10.1001/jamaoncol.2023.2150. PMID: 37440239; PMCID: PMC10346502.

Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, **Palleschi M**, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study. *Oncologist.* 2023 Nov 23;oyad308. doi: 10.1093/oncolo/oyad308. Epub ahead of print. PMID: 37995313.

Schettini F*, **Palleschi M***, Mannozi F, Brasó-Maristany F, Cecconetto L, Galván P, Mariotti M, Ferrari A, Scarpi E, Miserocchi A, Nanni O, Sanfeliu E, Prat A, Rocca A, De Giorgi U. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. *Oncologist.* 2024 Jan 4;oyad337. doi: 10.1093/oncolo/oyad337. Epub ahead of print. PMID: 38175669.

Maltoni R, Roncadori A, Balzi W, Mazza M, Nicolini F, **Palleschi M**, Ulivi P, Bravaccini S. An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy. *Biomedicines.* 2024 Feb 22;12(3):498. doi: 10.3390/biomedicines12030498. PMID: 38540112; PMCID: PMC10968497.

Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, Cortes J, Rossi V, **Palleschi M**, Alberini JL, Matteucci F, Piccardo A, Sacchetti G, Ilhan H, D'Avanzo F, Ruffilli B, Nardin S, Monti M, Puntoni M, Fontana V, Boni L, Harbeck N; ET-FES Collaborative Group. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET. *Ann Oncol.* 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.02.007. Epub ahead of print. PMID: 38423389.

Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, **Palleschi M**, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, Criscitiello C, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. *NPJ Breast Cancer.* 2024 Jul 17;10(1):58. doi: 10.1038/s41523-024-00657-z. Erratum in: *NPJ Breast Cancer.* 2024 Aug 2;10(1):68. doi: 10.1038/s41523-024-00682-y. PMID: 39019916; PMCID: PMC11254918.

Rossi A, Sancini G, Amadori E, Cenni P, **Palleschi M**, Prochowski Iamurri A. Breast Cancer Leptomeningeal Metastases on Spinal Epidural Lipomatosis. *Diagnostics (Basel).* 2024 Jul 12;14(14):1496. doi: 10.3390/diagnostics14141496. PMID: 39061633; PMCID: PMC11276335.

Sirico M, Jacobs F, Molinelli C, Nader-Marta G, Debieu V, Dewhurst HF, **Palleschi M**, Merloni F, Gianni C, De Giorgi U, de Azambuja E. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond. *Crit Rev Oncol Hematol*. 2024 Aug;200:104404. doi: 10.1016/j.critrevonc.2024.104404. Epub 2024 May 28. PMID: 38815877.

Filippo Merloni, **Michela Palleschi**, Caterina Gianni, Marianna Sirico, Riccardo Serra, Chiara Casadei, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Marita Mariotti, Roberta Maltoni, Daniela Montanari, Antonino Romeo, Ugo De Giorgi Local Treatment for Oligoprogressive Metastatic Sites of Breast Cancer: Efficacy, Toxicities And Future Perspectives. Accepted Sep 2024 [IN PRESS]. *Clinical & Experimental Metastasis*.

Plasma-SeqSensei NGS assay: a non-invasive tool to monitor resistance mechanisms to hormonal therapy and CDK4/6 inhibitors

Alessandra Virga *, Caterina Gianni, **Michela Palleschi**, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravaccini [accepted, in press] *Biomedicines* 2024.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Di Grazia G, Dri A, Grieco A, Martinelli C, **Palleschi M**, Martorana F, Barchiesi G, Arpino G, De Angelis C, De Laurentiis M, Del Mastro L, Puglisi F, Vigneri P, Giuliano M. *Cancers (Basel)*. 2025 Sep 8;17(17):2940. doi: 10.3390/cancers17172940.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.

Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricosi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, **Palleschi M**, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. *Breast*. 2025 Aug;82:104502. doi: 10.1016/j.breast.2025.104502. Epub 2025 May 15.

Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants.

Palleschi M, Virga A, Scarpi E, Fonzi E, Musolino A, Merloni F, Sarti S, Danesi R, Ravegnani M, Casadei C, Sirico M, Gianni C, Maltoni R, Bravaccini S, Calistri D, Arcangeli V, Zampiga V, Cangini I, Bandini E, Mannozi F, Falcini F, Martinelli G, De Giorgi U, Ulivi P, Tedaldi G.

Oncologist. 2025 May 8;30(5):oyaf052. doi: 10.1093/oncolo/oyaf052.

Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity.

Rossi T, Bandini S, Zanoni M, Cortesi M, **Palleschi M**, Bandini E, Rocca A, Gallerani G, Vannini I, Plousiou M, Gerratana L, Musolino A, Tallini G, Martinelli G, De Giorgi U, Ulivi P.

Exp Hematol Oncol. 2025 May 6;14(1):67. doi: 10.1186/s40164-025-00659-y.

Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review.
Scafuri L, Buonerba C, Strianese O, de Azambuja E, **Palleschi M**, Riccio V, Marotta V, Scocca C, Riccio G, Errico C, Arpino G, Di Lorenzo G.
Nutrients. 2025 Mar 11;17(6):981. doi: 10.3390/nu17060981.

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, D'Auria G, Fedele P, Fabbri A, Vernieri C, Palleschi M, Carbognin L, Ferretti G, Di Monte E, Paris I, Pavese F, Garrone O, Franco A, De Laurentiis M, Franceschini G, Scambia G, Giannarelli D, Masetti R, Botticelli A.
NPJ Precis Oncol. 2025 Jan 22;9(1):22. doi: 10.1038/s41698-025-00801-3.

HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer.
Cortesi M, Bravaccini S, Ravaioli S, Petracci E, Angeli D, Tumedei MM, Balzi W, Pirini F, Zanoni M, Possanzini P, Rocca A, **Palleschi M**, Ulivi P, Martinelli G, Maltoni R.
Cancers (Basel). 2024 Nov 6;16(22):3752. doi: 10.3390/cancers16223752.

The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. Crucitta S, Cinacchi P, Bargagna I, Biondani P, Giontella E, **Palleschi M**, Omarini C, Belluzzi L, Angelini L, Meattini I, Visani L, Stucci S, Porta C, Fontana A, De Giorgi U, Fogli S, Danesi R, Del Re M. Ther Adv Drug Saf. 2026 Apr 22;17:20420986251414591. doi: 10.1177/20420986251414591. eCollection 2026. PMID: 42051387
Free PMC article.

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Venuti F, Vilardi FA, Riconzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, La Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Chirco A, D'Alessandro S, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, **Palleschi M**, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Oncologist. 2026 Apr 10;31(5):oyag146. doi: 10.1093/oncolo/oyag146. PMID: 41992832 Free PMC article.

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2- breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. Scafetta R, Troiano R, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Donato M, Foderaro S, Venuti F, Vilardi FA, Riconzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Garrone O, Domati F, Piombino C, Lisa FSD, Filomeno L, Arcuri T, Puce F, Riva F, **Palleschi M**, Sirico M, Piras M, Stucci LS, Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Livi L, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri MA, Giorgi U, Vici P, Toss A, Ruatta F, Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Chirco A, D'Alessandro S, Vincenzi B, Tonini

G, Santini D, Pantano F. Eur J Cancer. 2026 May 15;239:116703. doi: 10.1016/j.ejca.2026.116703. Epub 2026 Mar 27. PMID: 41921366 Free article.

Clinical characteristics and drug-drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study.

Pisegna S, Scagnoli S, Gentile G, Chiavassa A, Caputo R, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Orlandi A, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, **Palleschi M**, Ballatore Z, Alesini D, D'Auria G, Fabbri MA, Rossi L, Fiscon G, Marchetti P, Fabi A, Botticelli A. Oncologist. 2026 Jan 17;31(2):oyaf402. doi: 10.1093/oncolo/oyaf402. PMID: 41587947 Free PMC article.

Survey on cancer patients' attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center. Cavallucci M, Andalò A, Danesi V, Gentili N, Massa I, Scarpi E, Restuccia MC, Vespignani R, Conficconi A, **Palleschi M**, De Giorgi U, Musolino A, Merloni F. Int J Med Inform. 2026 Apr 1;209:106237. doi: 10.1016/j.ijmedinf.2025.106237. Epub 2025 Dec 30. PMID: 41518823 Free article. Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.

Sarti S, Viansone AA, Serra O, Casadei C, Cecconetto L, Di Menna G, Farolfi A, Gianni C, Mariotti M, Merloni F, **Palleschi M**, Sirico M, Zoppoli G, Musolino A. Cancers (Basel). 2025 Nov 7;17(22):3597. doi: 10.3390/cancers17223597. PMID: 41300964 Free PMC article. Review.

Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.

Di Grazia G, Dri A, Grieco A, Martinelli C, **Palleschi M**, Martorana F, Barchiesi G, Arpino G, De Angelis C, De Laurentiis M, Del Mastro L, Puglisi F, Vigneri P, Giuliano M.

Cancers (Basel). 2025 Sep 8;17(17):2940. doi: 10.3390/cancers17172940. PMID: 40941037 Free PMC article. Review.

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, **Palleschi M**, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F.

Breast. 2025 Aug;82:104502. doi: 10.1016/j.breast.2025.104502. Epub 2025 May 15. PMID: 40424680 Free PMC article.

Autorizzo il trattamento dei miei dati personali ai sensi del D.lgs.196/2003. Ai sensi degli artt. 46 e 47 del D.P.R. n. 445/2000 dichiaro, sotto la mia responsabilità e consapevole delle sanzioni penali previste dall'art. 76 del D.P.R. 445/200, la veridicità delle informazioni e dei titoli indicati e autocertificati.

Meldola (FC), 26/05/2026

Michela Palleschi

Michela Palleschi